Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15691733 | 0.92 | ALDH1A1 (0.44) | MTTPALDH1A1MAPTITGA4APEX1 | |
| SCHEMBL15691695 | 0.86 | ALDH1A1 (0.46) | ALDH1A1MAPTITGA4PDK2APEX1 | |
| SCHEMBL5863337 | 0.86 | GLA (0.40) | MTTPALDH1A1MAPTPDK2 | |
| SCHEMBL17460359 | 0.85 | MTTP (0.39) | MTTPALDH1A1MAPTITGA4APEX1 | |
| SCHEMBL17050271 | 0.85 | MTTP (0.39) | MTTPALDH1A1MAPTITGA4APEX1 | |
| SCHEMBL5863723 | 0.81 | THRB (0.46) | MTTPPDK2APEX1 | |
| SCHEMBL6771465 | 0.81 | MTTP (0.47) | MTTP | |
| SCHEMBL6777657 | 0.80 | APEX1 (0.40) | MTTPAPEX1 | |
| SCHEMBL5863866 | 0.80 | APEX1 (0.40) | MTTPPDK2APEX1 | |
| SCHEMBL15691728 | 0.80 | APEX1 (0.51) | ALDH1A1MAPTITGA4PDK2APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016012934-A1 | PROCESS FOR MAKING LOMITAPIDE MESYLATE | MYLAN LABORATORIES LTD (IN) | 2016-01-28 | — | — | WO | disclosed |
| WO-2016012934-A1 | PROCESS FOR MAKING LOMITAPIDE MESYLATE | MYLAN LABORATORIES LTD (IN) | 2016-01-28 | — | — | WO | disclosed |
| US-20030114442-A1 | Substituted piperazine derivatives as mtp inhibitors | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114442-A1 | Substituted piperazine derivatives as mtp inhibitors | MTTP, CETP, LIPC | MTTP 1/4885ALDH1A1 738/4885MAPT 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.